The development of molecular diagnostics for antihelmintic drug resistance monitoring in human schistosomiasis.
The development of molecular diagnostics for antihelmintic drug resistance monitoring in human schistosomiasis.
批准号:
2444698
负责人:
金额:
$0.0万
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --
中文摘要
血吸虫病是一种被忽视的热带疾病,撒哈拉以南非洲的疾病负担最重。这种疾病是由属于血吸虫属的吸虫引起的。血吸虫病有一系列的临床表现,包括血尿和肝脏、脾脏等器官肿大。世界卫生组织估计,血吸虫病影响了生活在流行地区的7亿人口中的三分之一以上。唯一推荐的人类血吸虫病治疗方法是单剂量吡喹酮(PZQ),因为它可以用于治疗所有主要的血吸虫病。这种药物可以通过大规模药物管理(MDA)计划与治疗其他感染(如淋巴丝虫病)的药物一起使用。近年来,获得PZQ的机会大大改善。例如,制药公司Merck-KGaA将每年的捐赠从2000万片扩大到2.5亿片PZQ片剂。虽然这种覆盖率的增加有助于减轻症状的严重程度,但它增加了对血吸虫寄生虫的药物选择压力。MDA计划的规模扩大可能导致PZQ抗性寄生虫的出现。因此,有必要检测和跟踪抗药性血吸虫寄生虫的出现,以抵消血吸虫病控制计划的威胁。该项目以全球传染病健康为主题,有两个主要目标:1。发展以分子为基础的方法,用于早期检测血吸虫物种,并阐明与PZQ耐药性发展相关的遗传标记的存在和分布2。收集数据,指导今后在大规模药物管理血吸虫病控制项目中合理和明智使用吡喹酮的模式。该项目将应用基于分子的实验室,现场和计算工具来实现项目目标。工作最初将集中在获得蜗牛维护的技能,并在实验室建立PZQ耐药的多体菌株,并使用分子测定来确认拟议的和新的遗传标记。这将使我通过体内训练获得整个生物体生理学的技能。在此之后,将在接受MDA PZQ的地方性环境中进行实地工作,以阐明遗传标记的存在和分布。本研究所获得的数据可为今后在MDA项目中使用PZQ控制血吸虫病提供指导。这个项目将发展和扩大我在分子技术,统计和流行病学分析以及功能和计算基因组学方面的技能。我在医学寄生虫学硕士学位中获得了这些领域的基本经验,因此向专家学习将有利于发展我的跨学科技能。我计划充分利用这两个机构的可用资源; LSHTM和St乔治。我已经开始学习流行病学模块,并报名参加了寄生虫基因组学模块,以培养与该项目相关的技能。我还参加了一个可转移的技能课程,以帮助文献检索与更多的课程预订的未来。如果可能的话,我打算参加一个关于使用R程序的课程,以提高我的统计分析和定量技能。
英文摘要
Schistosomiasis is a neglected tropical disease where the highest burden of disease occurs in sub-Saharan Africa. This disease is caused by trematodes belonging to the genus Schistosoma. Schistosomiasis has a range of clinical forms including haematuria and enlargement of organs such as the liver and spleen. The WHO estimate that schistosomiasis affects over one third of the 700 million people living in endemic areas. The only recommended treatment for schistosomiasis in humans is a single dose of praziquantel (PZQ), as it can be used against all major species of schistosomiasis. The drug can be administered through mass drug administration (MDA) programmes alongside drugs to treat other infections such as lymphatic filariasis. In recent years, the access to PZQ has been greatly improved. For example, the pharmaceutical company Merck-KGaA have expanded the annual donation from 20 million to 250 million PZQ tablets. Although this increased coverage has aided in reducing severity of symptoms, it heightens the drug selection pressures on Schistosoma parasites. The scale up of MDA programs could lead to the emergence of PZQ resistant parasites. Therefore, there is a need to detect and track the emergence of resistant Schistosoma parasites in order counteract the threat of resistance to schistosomiasis control programs. This project comes under the theme of Global Infectious Health and has two main aims:1. Develop molecular-based approaches for early detection of Schistosoma species and elucidate the presence and distribution of genetic markers associated with the development of PZQ resistance2. To generate data to guide future models of rational and judicious use of praziquantel in mass drug administration schistosomiasis control programmes. The project will apply molecular-based laboratory, field and computational tools to achieve the project aims. Work will initially focus on gaining skills in snail maintenance and establishing a PZQ resistant schistosome strain in the laboratory and using molecular assays to confirm proposed and novel genetic markers. This will allow me to gain skills in whole organism physiology through in vivo training. Following this, field work in endemic settings receiving MDA of PZQ, will be undertaken in order to elucidate the presence and distribution of the genetic markers. The data generated during this project can guide the future use of PZQ in MDA programs to control schistosomiasis. This project will develop and broaden my skills in molecular techniques, statistical and epidemiological analysis as well as functional and computation genomics. I have basic experience in these areas achieved from my MSc Medical Parasitology so learning from experts will be beneficial in developing my interdisciplinary skillset.I plan to make the most of the resources available to me at both institutions; LSHTM and St George's. I have already begun epidemiology modules and have signed up to a parasite genomics module to develop skills relevant to the project. I have also attended a transferable skills course to aid in literature searching with more courses booked for the future. When it is possible, I intend to attend a course on using the program R in order to improve my statistical analysis and quantitative skills.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
配子生成素GGN不同位点突变损伤分子伴侣BIP及HSP90B1功能导致精子形成障碍的发病机理
-
批准号:82371616
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨成
-
依托单位:
MYRF/SLC7A11调控施万细胞铁死亡在三叉神经痛脱髓鞘病变中的作用和分子机制研究
-
批准号:82370981
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:陈敏洁
-
依托单位:
PET/MR多模态分子影像在阿尔茨海默病炎症机制中的研究
-
批准号:82372073
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:张淼
-
依托单位:
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
-
批准号:82371652
-
项目类别:面上项目
-
资助金额:45.00万元
-
批准年份:2023
-
负责人:刘开江
-
依托单位:
靶向PARylation介导的DNA损伤修复途径在恶性肿瘤治疗中的作用与分子机制研究
-
批准号:82373145
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:历鹏
-
依托单位:
OBSL1功能缺失导致多指(趾)畸形的分子机制及其临床诊断价值
-
批准号:82372328
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:项盈
-
依托单位:
O6-methyl-dGTP抑制胶质母细胞瘤的作用及分子机制研究
-
批准号:82304565
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:李瑾
-
依托单位:
转录因子LEF1低表达抑制HMGB1致子宫腺肌病患者子宫内膜容受性低下的分子机制
-
批准号:82371704
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:徐步芳
-
依托单位:
Irisin通过整合素调控黄河鲤肌纤维发育的分子机制研究
-
批准号:32303019
-
项目类别:青年科学基金项目
-
资助金额:30.00万元
-
批准年份:2023
-
负责人:职韶阳
-
依托单位:
上皮细胞黏着结构半桥粒在热激保护中的作用机制研究
-
批准号:31900545
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2019
-
负责人:傅容
-
依托单位: